Drugs & Targets Ocugen gets Orphan Drug designation for ocular graft vs. host disease September 01, 2017Vol.43 No.32
Drugs & Targets FDA acts to remove unproven treatment used in ‘stem cell’ centers September 01, 2017Vol.43 No.32
Drugs & Targets Enasidenib, companion diagnostic get FDA approval for relapsed or refractory AML August 04, 2017Vol.43 No.31
Drugs & Targets Vyxeos gets FDA approval for first treatment for types of poor-prognosis AML August 04, 2017Vol.43 No.31
Drugs & Targets Opdivo gets FDA accelerated approval for MSI-H/dMMR colorectal cancer August 04, 2017Vol.43 No.31
Drugs & Targets Amgen, Allergan submit biosimilar application for ABP 980 to FDA August 04, 2017Vol.43 No.31
Drugs & Targets Kite files the first CAR-T application in Europe for axicabtagene ciloleucel August 04, 2017Vol.43 No.31
Drugs & Targets BMS to acquire IFM Therapeutics to focus on innate immunity August 04, 2017Vol.43 No.31
Drugs & Targets BMS, Clovis form collaboration to evaluate Opdivo and Rubraca August 04, 2017Vol.43 No.31
